Martin Steinbuck

Title: Martin Steinbuck: Innovator in Cancer Treatment

Introduction

Martin Steinbuck is a notable inventor based in Boston, MA (US), recognized for his contributions to cancer treatment through innovative compounds. He holds 2 patents that focus on novel therapeutic approaches utilizing lipid-linked sequences.

Latest Patents

Steinbuck's latest patents include "CpG amphiphiles and uses thereof," which provides compounds that link a CpG oligodeoxynucleotide sequence to a lipid via a linker. This invention features a method for treating cancer in human patients by administering the compound, along with a pharmaceutical composition that includes the compound and a pharmaceutically acceptable carrier. Another significant patent is "Compounds including a mutant KRAS sequence and a lipid and uses thereof," which describes a compound that conjugates a mutant KRAS sequence to a lipid, specifically 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE). This invention also outlines a method for treating cancer by administering the composition to patients.

Career Highlights

Steinbuck is currently associated with Elicio Therapeutics, Inc., where he continues to develop innovative solutions for cancer treatment. His work is pivotal in advancing therapeutic strategies that target specific genetic sequences linked to cancer.

Collaborations

He collaborates with esteemed colleagues such as Peter C. Demuth and Julian Adams, contributing to a dynamic research environment focused on groundbreaking medical advancements.

Conclusion

Martin Steinbuck's innovative work in cancer treatment exemplifies the impact of targeted therapies in modern medicine. His patents reflect a commitment to improving patient outcomes through scientific discovery.